AN2 Therapeutics $70 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the joint book-running managers in connection with a $70 million SEC-registered follow-on offering of 7,777,778 shares of common stock by AN2 Therapeutics, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “ANTX.”
Based in Menlo Park, California, AN2 Therapeutics is a clinical-stage biotechnology company developing treatments for rare, chronic and serious infectious diseases with high unmet needs. Its initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial (NTM) lung disease.
The Davis Polk corporate team included partner Emily Roberts and associates Bex Childress and Rong (Fiona) Huang. The intellectual property team included partner David R. Bauer and associate Alison T. Chin. Members of the Davis Polk team are based in the Northern California and New York offices.